The Long Run with Luke Timmerman Ep162: Sean McClain on AI for Biologic Drug Discovery
16 snips
Jul 16, 2024 Sean McClain, CEO of Absci, discusses using AI to speed up biologic drug discovery. Topics include the upcoming clinical testing of an antibody drug for inflammatory bowel disease in 2025, integrating AI into drug discovery, the creative aspects of biologic drug discovery, engineering E. coli for biologic therapies, evolving business models in biologic drug discovery, unexpected discoveries in drug compound affinity, and revolutionizing drug discovery with AI-generated biologics.
AI Snips
Chapters
Transcript
Episode notes
Absci's Humble Beginnings
- Sean McClain started Absci in his early 20s with his dad's encouragement.
- It began as a scrappy garage biotech, developing assays for the biopharmaceutical industry.
Early Entrepreneurial Spirit
- McClain's dad encouraged him to start a lawn-mowing business at a young age.
- This experience taught him valuable lessons about sales and entrepreneurship.
Engineering Biology
- McClain's interest in engineering biology stemmed from a biochemistry class.
- He was inspired by the idea of applying engineering principles to living organisms.